Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.

The American Cancer Society estimates that about 30,770 new patients will be diagnosed with multiple myeloma (MM) and approximately 12,770 deaths will occur in the USA in 2018.1 Advances in understanding MM biology, drug development and improved supportive care have resulted in the prolongation of life of many patients with this disease but survival is variable, ranging from months to more than 10 years. 2-8 Contemporary prognostic models have been developed since the original Durie-Salmon Staging system published in 1975, which used commonly available clinical parameters including calcium, hemoglobin, bone lesions, creatinine level and serum or urine monoclonal protein.

Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Emma C. Scott, Parameswaran Hari, Sathish Kumar, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, Miguel Angel Diaz, Vaibhav Agrawal, Robert F. Cornell, Siddhartha Ganguly, Gorgun Akpek, Cesar Freytes, Shahrukh Hashmi, Ehsan Malek, Rammurti T. K Source Type: research